APO Research
Talk to an analyst

APO RESEARCH · REPORT

Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchPost-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Post-Polycythemia Vera Myelofibrosis (PPV-MF) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company

Novartis AG

Merck & Co Inc

AbbVie Inc

Sun Pharma Advanced Research Company Ltd

Promedior Inc

NS Pharma Inc

MEI Pharma Inc

MedImmune LLC

JW Pharmaceutical Corp

Italfarmaco SpA

Incyte Corp

Gilead Sciences Inc

F. Hoffmann-La Roche Ltd

CTI BioPharma Corp

Celgene Corp

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type

Idelalisib

Givinostat

Glasdegib

Durvalumab

IMG-7289

Others

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application

Hospital

Clinic

Others

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Post-Polycythemia Vera Myelofibrosis (PPV-MF) key companies, revenue, market share, and recent developments.

3. To split the Post-Polycythemia Vera Myelofibrosis (PPV-MF) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Post-Polycythemia Vera Myelofibrosis (PPV-MF) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Post-Polycythemia Vera Myelofibrosis (PPV-MF) significant trends, drivers, influence factors in global and regions.

6. To analyze Post-Polycythemia Vera Myelofibrosis (PPV-MF) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) industry.

Chapter 3: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Post-Polycythemia Vera Myelofibrosis (PPV-MF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Post-Polycythemia Vera Myelofibrosis (PPV-MF) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends Table 2. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers Table 3. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges Table 4. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints Table 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Company (2021-2026) Table 7. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Company Manufacturing Base & Headquarters Table 9. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company, Product Type & Application Table 10. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Idelalisib Table 15. Significant Companies of Givinostat Table 16. Significant Companies of Glasdegib Table 17. Significant Companies of Durvalumab Table 18. Significant Companies of IMG-7289 Table 19. Significant Companies of Others Table 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type (2021-2026) Table 24. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Table 26. Significant Companies of Clinic Table 27. Significant Companies of Others Table 28. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application (2021-2026) Table 32. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application (2027-2032) Table 33. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Region (2021-2026) Table 36. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Region (2027-2032) Table 38. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Market Share by Country (2021-2026) Table 41. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Market Share by Country (2027-2032) Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 47. Novartis AG Recent Development Table 48. Merck & Co Inc Company Information Table 49. Merck & Co Inc Business Overview Table 50. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 52. Merck & Co Inc Recent Development Table 53. AbbVie Inc Company Information Table 54. AbbVie Inc Business Overview Table 55. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 57. AbbVie Inc Recent Development Table 58. Sun Pharma Advanced Research Company Ltd Company Information Table 59. Sun Pharma Advanced Research Company Ltd Business Overview Table 60. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 62. Sun Pharma Advanced Research Company Ltd Recent Development Table 63. Promedior Inc Company Information Table 64. Promedior Inc Business Overview Table 65. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 67. Promedior Inc Recent Development Table 68. NS Pharma Inc Company Information Table 69. NS Pharma Inc Business Overview Table 70. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 72. NS Pharma Inc Recent Development Table 73. MEI Pharma Inc Company Information Table 74. MEI Pharma Inc Business Overview Table 75. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 77. MEI Pharma Inc Recent Development Table 78. MedImmune LLC Company Information Table 79. MedImmune LLC Business Overview Table 80. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 82. MedImmune LLC Recent Development Table 83. JW Pharmaceutical Corp Company Information Table 84. JW Pharmaceutical Corp Business Overview Table 85. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 87. JW Pharmaceutical Corp Recent Development Table 88. Italfarmaco SpA Company Information Table 89. Italfarmaco SpA Business Overview Table 90. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 92. Italfarmaco SpA Recent Development Table 93. Incyte Corp Company Information Table 94. Incyte Corp Business Overview Table 95. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 97. Incyte Corp Recent Development Table 98. Gilead Sciences Inc Company Information Table 99. Gilead Sciences Inc Business Overview Table 100. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 102. Gilead Sciences Inc Recent Development Table 103. F. Hoffmann-La Roche Ltd Company Information Table 104. F. Hoffmann-La Roche Ltd Business Overview Table 105. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 107. F. Hoffmann-La Roche Ltd Recent Development Table 108. CTI BioPharma Corp Company Information Table 109. CTI BioPharma Corp Business Overview Table 110. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 112. CTI BioPharma Corp Recent Development Table 113. Celgene Corp Company Information Table 114. Celgene Corp Business Overview Table 115. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 117. Celgene Corp Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Image Figure 2. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032) & (US$ Million) Figure 4. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Idelalisib Image Figure 8. Givinostat Image Figure 9. Glasdegib Image Figure 10. Durvalumab Image Figure 11. IMG-7289 Image Figure 12. Others Image Figure 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application (2021-2032) Figure 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032) & (US$ Million) Figure 25. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032) & (US$ Million) Figure 31. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Idelalisib
  • Givinostat
  • Glasdegib
  • Durvalumab
  • IMG-7289
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co Inc
  • AbbVie Inc
  • Sun Pharma Advanced Research Company Ltd
  • Promedior Inc
  • NS Pharma Inc
  • MEI Pharma Inc
  • MedImmune LLC
  • JW Pharmaceutical Corp
  • Italfarmaco SpA
  • Incyte Corp
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • CTI BioPharma Corp
  • Celgene Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
  1. 2.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
  2. 2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
  3. 2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
  4. 2.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints
3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Company
  1. 3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Revenue Ranking in 2025
  2. 3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Company (2021-2026)
  3. 3.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Ranking (2024-2026)
  4. 3.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Manufacturing Base and Headquarters
  5. 3.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Product Type and Application
  6. 3.6 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Type
  1. 4.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Type Introduction
  2. 4.1.1 Idelalisib
  3. 4.1.2 Givinostat
  4. 4.1.3 Glasdegib
  5. 4.1.4 Durvalumab
  6. 4.1.5 IMG-7289
  7. 4.1.6 Others
  8. 4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type
  9. 4.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Type (2021-2032)
  11. 4.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type (2021-2032)
5 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Application
  1. 5.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application
  6. 5.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application (2021-2032)
6 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Regional Value Analysis
  1. 6.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032)
  7. 6.3.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032)
  10. 6.4.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032)
  16. 6.6.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Country, 2025 VS 2032
7 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Country-level Value Analysis
  1. 7.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co Inc
  8. 8.2.1 Merck & Co Inc Company Information
  9. 8.2.2 Merck & Co Inc Business Overview
  10. 8.2.3 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  12. 8.2.5 Merck & Co Inc Recent Developments
  13. 8.3 AbbVie Inc
  14. 8.3.1 AbbVie Inc Company Information
  15. 8.3.2 AbbVie Inc Business Overview
  16. 8.3.3 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  18. 8.3.5 AbbVie Inc Recent Developments
  19. 8.4 Sun Pharma Advanced Research Company Ltd
  20. 8.4.1 Sun Pharma Advanced Research Company Ltd Company Information
  21. 8.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
  22. 8.4.3 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  24. 8.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
  25. 8.5 Promedior Inc
  26. 8.5.1 Promedior Inc Company Information
  27. 8.5.2 Promedior Inc Business Overview
  28. 8.5.3 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  30. 8.5.5 Promedior Inc Recent Developments
  31. 8.6 NS Pharma Inc
  32. 8.6.1 NS Pharma Inc Company Information
  33. 8.6.2 NS Pharma Inc Business Overview
  34. 8.6.3 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  36. 8.6.5 NS Pharma Inc Recent Developments
  37. 8.7 MEI Pharma Inc
  38. 8.7.1 MEI Pharma Inc Company Information
  39. 8.7.2 MEI Pharma Inc Business Overview
  40. 8.7.3 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  42. 8.7.5 MEI Pharma Inc Recent Developments
  43. 8.8 MedImmune LLC
  44. 8.8.1 MedImmune LLC Company Information
  45. 8.8.2 MedImmune LLC Business Overview
  46. 8.8.3 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  48. 8.8.5 MedImmune LLC Recent Developments
  49. 8.9 JW Pharmaceutical Corp
  50. 8.9.1 JW Pharmaceutical Corp Company Information
  51. 8.9.2 JW Pharmaceutical Corp Business Overview
  52. 8.9.3 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  54. 8.9.5 JW Pharmaceutical Corp Recent Developments
  55. 8.10 Italfarmaco SpA
  56. 8.10.1 Italfarmaco SpA Company Information
  57. 8.10.2 Italfarmaco SpA Business Overview
  58. 8.10.3 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  60. 8.10.5 Italfarmaco SpA Recent Developments
  61. 8.11 Incyte Corp
  62. 8.11.1 Incyte Corp Company Information
  63. 8.11.2 Incyte Corp Business Overview
  64. 8.11.3 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  66. 8.11.5 Incyte Corp Recent Developments
  67. 8.12 Gilead Sciences Inc
  68. 8.12.1 Gilead Sciences Inc Company Information
  69. 8.12.2 Gilead Sciences Inc Business Overview
  70. 8.12.3 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  72. 8.12.5 Gilead Sciences Inc Recent Developments
  73. 8.13 F. Hoffmann-La Roche Ltd
  74. 8.13.1 F. Hoffmann-La Roche Ltd Company Information
  75. 8.13.2 F. Hoffmann-La Roche Ltd Business Overview
  76. 8.13.3 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  78. 8.13.5 F. Hoffmann-La Roche Ltd Recent Developments
  79. 8.14 CTI BioPharma Corp
  80. 8.14.1 CTI BioPharma Corp Company Information
  81. 8.14.2 CTI BioPharma Corp Business Overview
  82. 8.14.3 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  84. 8.14.5 CTI BioPharma Corp Recent Developments
  85. 8.15 Celgene Corp
  86. 8.15.1 Celgene Corp Company Information
  87. 8.15.2 Celgene Corp Business Overview
  88. 8.15.3 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  90. 8.15.5 Celgene Corp Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst